title: The therapeutic potential of the Wnt signaling pathway in bone disorders.
abstract: The Wnt pathway plays a critical role in development and differentiation of many tissues, such as the gut, hair follicles, and bone. Increasing evidence indicates that Wnts may function as key regulators in osteogenic differentiation of mesenchymal stem cells and bone formation. Conversely, aberrant Wnt signaling is associated with many osteogenic pathologies. For example, genetic alterations in the Wnt signaling pathway lead to osteoporosis and osteopenia, while inactivating mutations of Wnt inhibitors result in a hyperostotic skeleton with increased bone mineral density. Hyperparathyroidism causes osteopenia via induction of the Wnt signaling pathway. Lithium, often used to treat bipolar disorder, blocks a Wnt antagonist, decreasing the patient's risk of fractures. Thus, manipulating the Wnt pathway may offer plenty therapeutic opportunities in treating bone disorders. In fact, induction of the Wnt signaling pathway or inhibition of Wnt antagonists has shown promise in treating bone metabolic disorders, including osteoporosis. For example, antibodies targeting the Wnt inhibitor Sclerostin lead to increased bone mineral density in post-menopausal women. However, such therapies targeting the Wnt pathway are not without risk, as genetic alternations may lead to over-activation of Wnt/β-catenin and its association with many tumors. It is conceivable that targeting Wnt inhibitors may predispose the individuals to tumorigenic phenotypes, at least in bone. Here, we review the roles of Wnt signaling in bone metabolic and pathologic processes, as well as the therapeutic potential for targeting Wnt pathway and its associated risks in bone diseases.
authors.affiliation: Molecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA.
authors.forename: Eric R
authors.initials: ER
authors.lastname: Wagner
authors.forename: Gaohui
authors.initials: G
authors.lastname: Zhu
authors.forename: Bing-Qiang
authors.initials: BQ
authors.lastname: Zhang
authors.forename: Qing
authors.initials: Q
authors.lastname: Luo
authors.forename: Qiong
authors.initials: Q
authors.lastname: Shi
authors.forename: Enyi
authors.initials: E
authors.lastname: Huang
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Gao
authors.forename: Jian-Li
authors.initials: JL
authors.lastname: Gao
authors.forename: Stephanie H
authors.initials: SH
authors.lastname: Kim
authors.forename: Farbod
authors.initials: F
authors.lastname: Rastegar
authors.forename: Ke
authors.initials: K
authors.lastname: Yang
authors.forename: Bai-Cheng
authors.initials: BC
authors.lastname: He
authors.forename: Liang
authors.initials: L
authors.lastname: Chen
authors.forename: Guo-Wei
authors.initials: GW
authors.lastname: Zuo
authors.forename: Yang
authors.initials: Y
authors.lastname: Bi
authors.forename: Yuxi
authors.initials: Y
authors.lastname: Su
authors.forename: Jinyong
authors.initials: J
authors.lastname: Luo
authors.forename: Xiaoji
authors.initials: X
authors.lastname: Luo
authors.forename: Jiayi
authors.initials: J
authors.lastname: Huang
authors.forename: Zhong-Liang
authors.initials: ZL
authors.lastname: Deng
authors.forename: Russell R
authors.initials: RR
authors.lastname: Reid
authors.forename: Hue H
authors.initials: HH
authors.lastname: Luu
authors.forename: Rex C
authors.initials: RC
authors.lastname: Haydon
authors.forename: Tong-Chuan
authors.initials: TC
authors.lastname: He
mesh_terms: D001847:Bone Diseases / Q000473:pathology / Q000628:therapy*; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology; D015398:Signal Transduction / Q000187:drug effects; D051153:Wnt Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology
chemical_list: D051153:Wnt Proteins